CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical... ByInvesting.com • 17 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CRISPR Therapeutics AG (CRSP) closed at $43.42 in the latest trading session, marking a -1.83% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.29%.

16.0% of Oncternal Therapeutics shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 11.2% of Oncternal ...

A Google parent-owned startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end, marking a significant milestone in pharmaceutical development as ...

NASDAQ:CRSP opened at $41.51 on Wednesday. CRISPR Therapeutics AG has a one year low of $36.52 and a one year high of $91.10. The company has a market cap of $3.54 billion, a PE ratio of -14.67 ...

They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...

The right to citizenship by birth was established under the 14th Amendment, and the AG’s office claims that President Trump’s executive order to abolish it is a violation of the U.S ...

It is a settled right in our Constitution and recognized by the Supreme Court for more than a century,” AG Campbell said. “President Trump does not have the authority to take away ...